Mersana Therapeutics, Inc. (NASDAQ:MRSN) headquartered in Cambridge, will host a conference call for the investment community to discuss the 2Q20 earnings result on 7th August 2020 at 8:00 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.mersana.com
Earnings Expectation
Mersana Therapeutics, Inc. is reporting second quarter financial results on Friday 7th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, MRSN is expected to report 2Q20 loss of $ 0.3 per share from revenue of $ 0.30 million.
For the full year, analysts anticipate top line of $ 0.79 million, while looking forward to loss of $ 1.22 per share bottom line.
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications.
